skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Everolimus – a new approach in the treatment of renal cell carcinoma

Review

(3738) Views  (1073) Full article downloads

Authors: G Anandappa, AE Hollingdale, TG Eisen

Published Date March 2010 Volume 2010:2 Pages 61 - 70
DOI: http://dx.doi.org/10.2147/CMAR.S6047

G Anandappa, AE Hollingdale, TG Eisen

Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

Abstract: With the increasing understanding of the biology of the disease and the development of targeted therapy, there has been a paradigm shift in the treatment of clear cell metastatic renal cell carcinoma (mRCC). Traditionally patients with metastatic RCC have been treated with immunotherapy which has limited efficacy. The multikinase inhibitors sunitinib, sorafenib and pazopanib, the VEGF antibody bevacizumab in combination with interferon and the mTOR inhibitor temsirolimus have all been shown to prolong progression-free survival in phase III studies. Here we review another mTOR inhibitor, everolimus (Afinitor®; Novartis, USA) which was approved in March 2009 by the US FDA for treatment of targeted-therapy refractory metastatic renal cell cancer. The phase III study of everolimus (the RECORD study) was terminated early after a significant difference in efficacy was noted in the treatment arm with everolimus (progression-free survival of 4.0 months in patients on the treatment arm vs 1.9 months in the placebo arm). The most common adverse events were stomatitis, pneumonitis, fatigue and infections. We review Phase I–III data with a particular emphasis on safety data and patient focused outcomes.

Keywords: metastatic renal cell carcinoma, targeted therapy, mTOR, everolimus








Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Use of human protein C concentrates in the treatment of patients with severe congenital protein C deficiency
Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumab
Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection
Vesicular stomatitis virus modified with single chain IL-23 exhibits oncolytic activity against tumor cells in vitro and in vivo
Does smoking really protect from recurrent aphthous stomatitis?
From antiangiogenesis to hypoxia: current research and future directions
Long-term outcome of everolimus treatment in transplant patients
Comparison of the impact of radiotherapy and radiochemotherapy on the quality of life of 1-year survivors with cervical cancer
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University